This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Valeant Pharmaceuticals International, Inc.
Drug Names(s): diltiazem hydrochloride
Description: Cardizem is a calcium ion influx inhibitor (slow channel blocker or calcium antagonist). It produces its antihypertensive effect primarily by relaxation of vascular smooth muccle and the resultant decrease in preipheral vascular resistance. Carizem has been shown to produce increases in exercise tolerance, probably due to its ability to reduce myocardial oxygen demand.
Deal Structure: In June 2010, Valeant and Biovail announced that both companies' Boards of Directors have unanimously approved a definitive merger agreement under which the companies would combine to generate enhanced value for stockholders. The combined company will be called Valeant Pharmaceuticals International. This acquisition closed in September 2010.
Pink Sheet Will FTC Shakeup Impact Pharma?
Additional information available to subscribers only: